Cereno Scientific expands patent rights for CS1
| Published December 20, 2021

Cereno Scientific extends patent protection for CS1

While the CS1 lead program is being evaluated in Phase II, Cereno Scientific is working to secure its commercial positioning for the future. Throughout 2021, the biotech company has expanded its CS1 patent portfolio so that the first two patent families now cover most major global markets. Last week, Cereno also announced that it has now received its first patent approval within the third patent family for CS1.

Cereno Scientific continues to achieve new milestones on the journey towards taking CS1 to the market. The drug candidate targets a broad spectrum of cardiovascular diseases (CVD) and this year, in addition to initiating a phase II study in patients with pulmonary arterial hypertension (PAH), the company has continued to strengthen the intellectual property rights (IR) around CS1.

First patent in CS1's third patent family granted

During the year, Cereno has successfully secured patent protection for CS1 through its first two patent families in most major global markets, including the US, Japan, Canada, Australia, Russia and 15 European countries. Last week, the company also announced that it has also obtained IR protection for the third patent family related to CS1 in the Russian market. The patent, titled Delayed release pharmaceutical formulations comprising valproic acid and uses thereof, is valid until 2037, with the possibility of an extension for another five years.

Cereno CEO Sten R. Sörensen was very pleased with the news:

»It is great to see how our continuous work to secure the intellectual property protection of our portfolio is bearing fruit and further strengthening the patent protection for CS1 in the Russian market.«

Jonas Faijerson Säljö, Chief Intellectual Property Officer at Cereno Scientific and responsible for the company's IR strategy, also commented on the patent announcement:

»A comprehensive and strong patent portfolio is a key factor in protecting the significant investments that the development and launch of new medicines require. That is why we are very pleased to extend our extensive patent protection to the third patent family for CS1.«

Read more about Cereno's IR strategy, including an interview with Jonas Faijerson Säljö here.

Increased value for the company

For pharmaceutical and biotechnology companies, a strengthened IP portfolio means better protection of the technology (method, compound, formulation, etc.) used in the development of their pharmaceutical products. This, in turn, leads to a stronger position in the market once the product receives market approval. The expansion of Cereno's patent portfolio for CS1, to now include three patent families, is therefore a significant value driver for the company.